Morgan Stanley Reiterates Overweight Rating on Watson Pharmaceuticals
December 31, 2012 at 15:13 PM EST
In a report published Monday, Morgan Stanley reiterated its Overweight rating on Watson Pharmaceuticals (NYSE: WPI ). Morgan Stanley noted, “We did not know that Covidien was pursuing generic Concerta (we were not aware of any Paragraph IV litigation), nor that it would qualify for exclusivity on the 27, 36,
